Myocardial Injury Depends on Valve Type in Transfemoral TAVR

Share this content:
Myocardial Injury Depends on Valve Type in Transfemoral TAVR
Myocardial Injury Depends on Valve Type in Transfemoral TAVR

WEDNESDAY, Aug. 9, 2017 (HealthDay News) -- Myocardial injury occurs frequently following transfemoral (TF) transcatheter aortic valve replacement (TAVR), but does not predict outcome, according to a study published in the Aug. 14 issue of JACC: Cardiovascular Interventions.

Anja Stundl, M.D., from Heart Center Bonn in Germany, and colleagues measured cardiac high-sensitivity troponin I (hsTnI) and creatine kinase MB (CK-MB) levels at pre-defined time points in 756 consecutive TF TAVR patients to assess the occurrence of myocardial injury during the first 72 hours.

The researchers found that hsTnI and CK-MB were elevated in 51.6 and 7.4 percent of patients, respectively, after uneventful TF TAVR. There was a correlation for myocardial injury with transcatheter heart valve (THV) type: Patients who received LOTUS THV more often had myocardial injury (LOTUS, 81.6 percent; Direct Flow Medical, 56.4 percent; CoreValve, 51.2 percent; Evolut R, 42.7 percent; SAPIEN XT, 40.4 percent; SAPIEN 3, 36.6 percent; P < 0.001). There was no correlation for myocardial injury defined by hsTnI with adverse outcomes at 30 days (3.1 versus 2.7 percent; P = 0.778) or one year (16.7 versus 17.2 percent; P = 0.841). An increase in CK-MB was also not associated with mortality at 30 days (5.5 versus 2.8 percent; P = 0.258) or one year (16.4 versus 17.3 percent; P = 0.856).

"The extent of cardiac biomarker elevation depends on THV type but is not associated with adverse short- and long-term outcomes after uneventful TAVR," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »